@article{PCM4920,
author = {Eric Santoni-Rugiu},
title = {Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma},
journal = {Precision Cancer Medicine},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {Despite very high response rate (RR) and significant clinical benefit of EGFR-tyrosine-kinase inhibitors (TKIs) in patients with advanced EGFR-mutated (EGFRM+) non-small cell lung cancer (NSCLC) of adenocarcinoma (LAC) type, virtually all cases become resistant to these drugs with a median progression-free survival (PFS) of 9–13 months.},
issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/4920}
}